Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|6|6|678-686

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.6, Iss.6, 2015-11, pp. : 678-686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histological transformation from non‐small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 800-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 709-714

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 278-283

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 319-326

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 228-233

John Wiley & Sons Inc

Access to resources Recommend Favorite